



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 03rd March, 2022

“SAY NO TO CORRUPTION”

Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 101st meeting held on 23rd December, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No (1)	Brand name (2)	Decision (3)
(For Export Purpose Only)		
M/s Nugen Nutraceutical, 28km Ferozpur Road, Lahore		
1.	MEMORIN Capsules	Deferred for further deliberation on Gamma aminobutyric acid – GABA as dietary supplement
For Export Facilitation (Local)		
M/s Wilshire Laboratories, Lahore		
2.	BYLO GOLD Sachet	Deferred for provision of monograph of phospholipids
3.	Benfoxin Capsule	Deferred for benfotiamin as nutraceutical and its monograph
M/s Damac Healthcare, Plot#5, Street # N-1 E1, RCCI, Rawat.		
4.	Damac's DEBONE SACHET	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed. Provide Stability undertaking on Company's letter head duly signed by the owner of the firm.
5.	Damac's O SLIM SACHET	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed. Provide monograph of Glucomannan Provide Stability undertaking on Company's letter head duly signed by the owner of the firm.
6.	Damac's MAC FERT SACHET	EEC decided to defer the application for enlistment for the change of brand name.
7.	Damac's D-SLIM CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
8.	Damac's DEBONE TABLET	EEC decided to defer the application for enlistment for the change of brand name.
M/s RG Pharmaceuticals (Pvt) Ltd., Plot No. 217 Sunder Industrial Estate, Lahore		
9.	PURA-MCT SYRUP	EEC decided the deferred the application on following reasons: Justify the applied formulation as nutraceutical health product. Specify the source of Medium Chain Triglyceride also provide the COA and Monograph as dietary supplement of the source, accordingly submitted revised form-3
M/S Oasis Pharma 23-Km Raiwind Road, Lahore. (E.No.00779)		
10.	SPAZIB CAPSULE	EEC decided to deferred for Clarification of formulation as to how Peppermint oil can be manufactured in Hard gelatin capsules. Specially regarding stability peppermint oil.
M/s Zonex Pharma (Pvt) Ltd, Lahore		

S.No (1)	Brand name (2)	Decision (3)
11.	Rmz Colic Drop	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
12.	Leucodil Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Method of testing of herbal extracts are required Certificate of analysis of Finished product is required
M/s S. Asia Oriental Pharma, Mosa Dhok Ghulam Ali, P.O Sagari, Rawalpindi (E. No. 00354)		
13.	COUGH CURE (VET) Oral Liquid	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
14.	GYNO LINK (VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Stamped form 3 is required • Brand name needs to be changed
15.	CENTA LINK (VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Stamped form 3 is required • Provide monograph of all ingredients and submit revise form-3 w.r.t specification of each ingredient as per monograph.
16.	SA STOMACH(VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • signed and Stamped form 3 is required • Provide monograph of all ingredients
17.	SA HEAT(VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Stamped form 3 is required
18.	SA JAIR (VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Stamped form 3 is required • Provide monograph of all ingredients
19.	GEST LINK (VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • As per form 3 firm still using Nux vomica in higher strength,safety profile and justification of product is still not provided • Stamped form 3 is required
20.	AJ GOO-Pain (VET) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • signed and Stamped form 3 is required • Provide monograph of all ingredients • Brand name change
21.	Energic Plus (Vet) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • Stamped form 3 is required
22.	Milko Link (Vet) Oral Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
M/s MSG Nutraceuticals, Islamabad		
23.	Oseomax Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
24.	U-Cid Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change

S.No (1)	Brand name (2)	Decision (3)
25.	Alexa Plus Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
26.	Rose Met Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
27.	Adcorin Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
28.	Bulus Plus Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name changed • The applied formulation contains Yohumbine which is common molecule
M/s Nutrabiotics Nutritional Life Sciences, Peshawar		
29.	Hsn Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Evidence of fee submission Endorsed by budget and account department
30.	Colifix Plus Drop	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Evidence of fee submission Endorsed by budget and account department • As per provided form 3 firm still using crude herbs, Monograph of extracts of active ingredients are required
31.	A-Ziar Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Evidence of fee submission Endorsed by budget and account department
32.	Conceive-Fm Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Evidence of fee submission Endorsed by budget and account department
33.	Ovasif Capsule	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Evidence of fee submission Endorsed by budget and account department
34.	Sebex Capsule	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Monograph of extract of damiana and chlorophytum borivilianum is required along with COA and Method of testing
M/s Classic Nutraceutical Labs, Peshawar		
35.	Colic Green Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Evidence of fee submission along with R&I receiving • Form 3 signed and stamped • Undertaking(notarized) regarding content and brand name • Monographs of active ingredients Brand name change
M/s Cosmo Pharma International Pvt Ltd, Karachi		
36.	Piles-Ye Cream	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of Sulphur rich oil shale extract,arachishypogea extract,szyggium aromatic extract,mentha arvensis extract are required Properly filled signed and stamped form 3 is required
37.	Piles-Ex Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change

S.No (1)	Brand name (2)	Decision (3)
38.	Super Warts Remover	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • Safety profile of Phenol used in formulation • Fee submission along with R&I receiving • Form 3 signed and stamped • Undertaking notarized for content of dossier and brand name
M/s Gluck Laboratories Pvt Ltd, Lahore		
39.	Glufer Syrup	EEC decided to defer the application for submission of following shortcomings: <ul style="list-style-type: none"> • As per form 3 the applied formulation is Ferric ammonium citrate as single ingredient common molecule
40.	Appup Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
41.	Apifed Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
M/s Himont Laboratories, Lahore		
42.	Dr. Koff Lozenges	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • Section approval letter of Lozenges section
43.	Caripeptic Chewabale Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • As per provided form 3, Firm still using crude herbs, Monograph of extracts of active ingredients are required along with COA and method of testing
M/s Trends Pharmaceuticals Lahore		
44.	Vifit-D Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
M/s Haven Pharmaceuticals Pvt. Ltd., Plot No. 65-A, M-3, Industrial Estate, Sahianwala, Faisalabad (E. No. 00985)		
45.	Act Fast Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
46.	Joint-Fit Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
47.	Orthocare Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
48.	Ortho-Nil Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
49.	Pain-Stat Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
50.	Pain-Nil Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
51.	Relaxor Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
52.	Xtra Fast Gel	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
M/s Innova Life Sciences, Lahore		

S.No (1)	Brand name (2)	Decision (3)
53.	Sunid Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
54.	Vigosun Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required
55.	Nugel Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required
M/s Bio-Med Pharma, Plot No.DP-28/1, Sector 12 C, North Karachi Industrial Area, Karachi-Pakistan. (E. No.00623)		
56.	BIO-MED PHARMA WRINK-MED CREAM	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: Brand name change
57.	BIO-MED Pharma PAN-MED	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: Brand name change
58.	BIO-MED Pharma FUN-MED Cream	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: Brand name change
59.	BIO-MED PHARMA D-MED Cream	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: Brand name change
60.	BIO MED PHARMA WITSOL Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
61.	BIOMED Pharma USICURE Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
62.	BIO MED PHARMA IRROTONE Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
63.	BIO-MED PHARMA BIO-CID SACHET	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • Monographs as required not provided
64.	BIO-MED PHARMA BIOCAL SACHET	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change
65.	Bio Med's MH-Collagen Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: Monograph of collagen is required
M/s MS Laboratories, St.No.28, Nisar Colony Industrial Area, Samanabad, Faisalabad. (E. No. 00551)		
66.	MS EASY BREATH TABLETS	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • According to NOTIFICATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
67.	MS ANTI-ALLERGIC SYRUP	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: <ul style="list-style-type: none"> • Brand name change • According to NOTIFICATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in

S.No (1)	Brand name (2)	Decision (3)
		<p>support of the claim of availability of the proposed combination in local market for last 10years,</p> <ul style="list-style-type: none"> • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
68.	MS ASHOKA CORDIAL SYRUP	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • Brand name change • According to NOTIFICATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
69.	MS BLATTA SYRUP	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • According to NOTIFICATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
70.	MS KIDNEX SYRUP	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • According to NOTIFICATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
M/s Bio Natural Solution, Islamabad		
71.	Fam Live Plus Liquid	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • Brand name change
72.	Electro Cf Liquid	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • The applied formulation contains sodium Hydrogen carbonate which is in list of common molecule deferred till the finalization of policy decision regarding common molecule
73.	Fam Immune Oral Solution	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • Brand name change
74.	Fibro Mass Powder	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • Brand name change
75.	Urimide Powder	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • Brand name change • The applied formulation contains Ammonium chloride which is common molecule
76.	Penta Max Powder	<p>EEC decided to defer the application and to give final opportunity for submission of following shortcomings:</p> <ul style="list-style-type: none"> • Brand name change

S.No (1)	Brand name (2)	Decision (3)
M/s Miksons Healthcare SMC (Pvt) Ltd, Islamabad		
77.	Bonecure Syrup	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Brand name change
78.	Osteo Grip Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Brand name change • Evidence of fee submission along with R&I receiving is required
79.	Sanmax Powder	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Brand name change
80.	Dawn-D Tablet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Brand name change
81.	Mikcal Sachet	EEC decided to defer the application for enlistment due to following reasons: • Evidence of fee submission is required Monograph of calcium citrate maleate is required
82.	Multivit Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Brand name change
83.	Ova Life Sachet	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Brand name change
M/s. Nutrifactor Laboratories (Pvt) Ltd., Plot No 4-B, Value Addition City, Khurrianwala, Faisalabad (E. No. 00324)		
84.	APPLE CIDER VINEGAR GUMMIES	EEC decided to defer the application and to give final opportunity for submission of following shortcomings: • Justify the use of "Organic Pomegranate" as nutraceutical ingredient. Also specify the exact form (extract, oil, powder, crude etc.) in which it is being used in the formulation COA along with Method of testing of finished product is required
M/s SOIS Life Sciences (Pvt) Ltd Plot No. A-84, S.I.T.E, Phase-I, Super Highway, Karachi (00090)		
85.	Dr-D Sachet	Deferred with final opportunity for change of brand name
86.	Aminowhey Sachet	Deferred with final opportunity for the following reasons: • Verify the branch chain amino acid. • The ingredients of formulation applied on Form-3 and that in master formula are different.
87.	Maxi life Tablet	Deferred till finalization of policy guidelines regarding common molecules
88.	Silyliv-L syrup	Deferred with final opportunity till finalization of policy regarding common molecules
89.	Dice-G tablet	Deferred till finalization of policy regarding common molecules
M/s. Arshzik (Veterinary), 23 Km Near Al-Ghani CNG, G.T. Road, Rawat, Rawalpindi (00302)		
90.	Arshzik's Rapid Booster liquid	Deferred with final opportunity for change of brand name. Vitamin A and Vitamin D3 are above RDA values.
91.	Arshzik's Bio-Virox BM Liquid	Deferred with final opportunity for submission of testing monograph of citrus extract and garlic extract.
M/s. Hiranis Pharmaceuticals (Pvt.) Ltd. E-145-149, North Western Industrial Zone, Port Qasim, Karachi (00174)		
92.	Ostino Tablet	Deferred with final opportunity for change of brand name and justification of formulation per two tablets
93.	Samvy CF Syrup	Deferred with final opportunity for verification of herbal syrup section.
94.	Samvy EMC syrup	Deferred with final opportunity for submission of fee receipt, official monographs of ingredients and undertakings
95.	Vid-Tress oral drops	Deferred with final opportunity for verification of Nutraceutical Oral liquid section
96.	Boncal Plus Tablet	Deferred with final opportunity for submission of fee receipt, official monographs of ingredients and undertakings
M/s. Zestech Sciences Plot No. 48. Sector 23, Korangi Industrial Area, Karachi (E. No. 00117)		

S.No (1)	Brand name (2)	Decision (3)
97.	Zamvit Oral Drops	Deferred with final opportunity for: <ul style="list-style-type: none"> Form 3 needs to be revised w.r.t showing specification and strength of active ingredients in formulation Stability studies data submission undertaking is required.
M/s. Adcok Pharmaceuticals (Pvt) Ltd Plot No 3-3-km, Defence off Raiwind Road, Near Lahore Univerisity Lahore (E. No. 00326)		
98.	Adcock's OSTIN Tablet	Deferred with final opportunity for submission of Form-3 and Official monograph of Egg shell membrane
99.	Adcok's Anorexin Syrup	Deferred with final opportunity for provision of official monographs of extracts of herbs and change of brand name
100.	Adcok's HAIOCID SYRUP	Deferred till finalization of policy regarding common molecules.
101.	Adcok's Z-Optal Syrup	Deferred with final opportunity for provision of official monograph of Xanthophyll
102.	Adcok's ALFATE SUSPENTION	Deferred with final opportunity for submission of official monographs of revised formulation
103.	Adcok's IVY REX PLUS Syrup/PROLEAF SYRUP	Deferred with final opportunity for: <ul style="list-style-type: none"> provision of revised Form-3. Official monographs of extracts of herbs. Till finalization of policy regarding common molecules.
104.	Adcok's LACTOR SYRUP 120 ml	Deferred with final opportunity for differential fee and official monographs of ingredients.
105.	Adcok's Repril 40mg Tablet	Deferred with final opportunity for change of brand name
M/s BIONS (Bio Natural Solution), Plot No. 15, 1-Km Bhangeeel Road, T-Chowk, Rawat, Islamabad (E. No. 00261)		
106.	PRO 50 % POWDER	Deferred with final opportunity for clarification of formulation and ingredients quantities as to what is meant by Crude protein, ash, fiber oils and fats.
107.	SE IMMUNE Liquid	Deferred with final opportunity for change of brand name
108.	RESP – EASE Liquid	Deferred with final opportunity for change of brand name
M/s. Royal Laboratories, 22-24 Farooq Industrial Estate, 20 Km Ferozepur Road, Lahore (00301)		
109.	Alkin Suspension	Deferred with final opportunity for provision of contents undertaking
110.	Coft syrup	Deferred with final opportunity for provision of contents undertaking
111.	Hemofin Plus Syrup	Deferred with final opportunity for change of brand name
112.	Nero-Gink Syrup	Deferred with final opportunity for the provision of fee receipt and contents undertaking
M/s Nascon Pharmaceutical (Natural Division) Plot No.66-A, Industrial Estate Hayatabad, Peshawar (00359)		
113.	Pedia Fresh Liquid	Deferred till finalization of policy regarding common molecules
114.	NASCAL-D SYRUP	Deferred with final opportunity for provision of stability studies data, contents and brand name undertaking, official monograph of coral calcium
115.	NASCUF Syrup	Deferred with final opportunity for provision of contents and brand name undertakings
116.	ICORISE Syrup	Deferred with final opportunity for provision of contents and brand name undertakings
M/s. Xecutive Pharma 171-S, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore (00312)		
117.	Lacto Act Syrup	Deferred with final opportunity for: <ul style="list-style-type: none"> The firm has not submitted the previous R&I receiving copy and fee receipt copy. The ingredients on Form-3 and in master formula are different. The stability studies data undertaking contents are not correct. The contents and brand name undertakings are not provided. Official monographs of active ingredients are required.
M/s Feroza International Pharmaceuticals (Pvt) Ltd., 33Km, Ferozepur Road, Lahore (00352)		
118.	FOLIMAX TABLET	DEFERRED FOR CHANGE OF BRAND NAME
119.	PEDIA-FER ORAL SOLUTION	Deferred till finalization of the Policy guidelines regarding common molecules.
120.	GASTROLAX SYRUP	Deferred for change of brand name
121.	DAILY MAXIMUM TABLET	Deferred for change of brand name
122.	FEROFOL DROP	Deferred for change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
123.	BONCAL-D TABLET	Deferred for change of brand name
124.	APPLE FORTE SYRUP	Deferred for change of brand name
M/s Hinucon (E. No. 0062)		
Plot No. 12/1, Sector 15, Korangi Industrial Area, Karachi		
125.	BACIPRO DROPS	Deferred for verification of probiotic section
126.	BACIPRO 2B SUSPENSION	Deferred for verification of probiotic section
127.	BACIPRO CAPSULE	Deferred for verification of probiotic section
128.	BACIPRO SACHET	Deferred for verification of probiotic section
129.	VEEKO-Z TABLET	Deferred for verification of probiotic section
M/s Health Supplement incorporated S 38A, 2nd floor Shahnaz Arcade Shaheed-e-Millat Road Karachi agent of M/s Captek Softgel international, 16218 Arthur street Cerritos, CA 90703, USA (E. No. 00469)		
130.	VitaKids Multivitamin Gummies	Deferred with final opportunity for following reasons: i. COA of finished product depicts that brand name is Children's Pectin Multi-Vitamin 2/5 LBS while given on Form 5 is VitaKids Multivitamin Gummies, needs clarification in this regards. ii. Long term and Accelerated stability studies of the said product is required as per the requirement of Zone IV A. iii. Authorized Distributor Agreement between principal manufacturer and distributor does not show authorization of said product for sale in Pakistan, needs clarification in this regards. Copy of Free Sale Certificate issued by Department of Public Health, California, USA shows that Vitakids Gummy Vitamins (does not match with applied brand name) is available in different flavors i.e, Lemon, orange, Strawberry, Cherry and Grape flavors and pack size is 60 Gummies (applied pack sizes are 30's, 60, 1000's), needs clarification in this regards.
131.	VitaKids Vitamin D3 Gummies	Deferred with final opportunity for following reasons: i. COA of finished product depicts that brand name is Pectin Vitamin D3 while given on Form 5 is VitaKids Vitamin D3 Gummies, needs clarification in this regards. ii. Long term and Accelerated stability studies of the said product is required as per the requirement of Zone IV A. iii. Authorized Distributor Agreement between principal manufacturer and distributor does not show authorization of said product for sale in Pakistan, needs clarification in this regards. Free sale certificate of said product attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan is required.
M/s Zuram Brothers., located at the address, 522-Hamza Block, Street No. 6, Green View Colony, Faisalabad agent of M/s Difagri Parc d'activite des Marches de Bretagnes 499 rue des Valois 85600 Saint Hilaire Deloulay, France (E. No. 01030)		
132.	Sorbitonic	Deferred with final opportunity for the provision of following documents: i. COA of Finished product is required. ii. Long Term Stability Studies data according to requirement of Zone IV A should be following : iii. Every 3 Months in first year, Every 6 months in second year and every year thereafter. iv. Free Sale certificate does not show any statement that product is freely available in the country of origin, needs clarification in this regards.
133.	Organselen E	Deferred with final opportunity for following reasons: i. COA of Finished product is required. ii. Long Term Stability Studies data according to requirement of Zone IV A. iii. Free Sale certificate does not show any statement that product is freely available in the country of origin, needs clarification in this regards.
134.	Diluphos	Deferred with final opportunity for following reasons: i. COA of Finished product is required. ii. Long Term Stability Studies data according to requirement of Zone IV A should be following :

S.No (1)	Brand name (2)	Decision (3)
		iii. Every 3 Months in first year, Every 6 months in second year and every year thereafter. iv. Free Sale certificate does not show any statement that product is freely available in the country of origin, needs clarification in this regards.
135.	Orgacool	Deferred with final opportunity for following reasons: i. COA of Finished product is required. ii. Long Term Stability Studies data according to requirement of Zone IV A. iii. Free Sale certificate does not show any statement that product is freely available in the country of origin, needs clarification in this regards.
M/s IBKB (Pvt.) Ltd., located at Basement 963, L.M.A, Johar Town, Lahore agent of M/s Impextraco, located at Wiekevorstsesteenweg 38, 2220 Heist-op-den-Berg, Belgium (E. No. 01002)		
136.	Add Aqua Vit C 25%	Deferred with final opportunity for the following reasons: i. Long Term Stability studies data according to the requirement of Zone IV A is required.
M/s Glaxo SmithKline Pakistan Limited, 35-Dakyard Road, West Wharf, Karachi-74000 agent of M/s SmithKline, Beecham Pvt, Ltd. Colombo , Srilanka (E. No. 0010)		
137.	Herb Active Balm	Deferred with final opportunity for following reasons: i. Brand name mentioned on COA, Stability studies is Iodex Double, while name mentioned on Form 5 is Herb Active Balm, needs clarification in this regards. ii. Power/iodex balm iii. Wintergreen Oil (Methyl Salicylate) is added in the list of common molecule. iv. Original and Valid Free sale certificate of said product to be attested by the regulatory body in the country of origin and countersigned by the embassy of Pakistan in country of origin.
138.	Iodex Quick Pain Relief Balm	Deferred with final opportunity for following reasons: i. Wintergreen Oil (Methyl Salicylate) is added in the list of common molecule. ii. Free sale certificate issued by Department of Ayurveda, Sri Lanka reveals that iodex Quick Pain Relief Balm is freely sold in Sri Lanka, in this regard it is submitted that a product under the brand name of Iodex was registered in the name of M/s GSK in Pakistan as pharmaceutical drug product. As per policy, same brand name cannot be allowed to Health & OTC Division product. iii. Brand name mentioned on COA, Stability studies is Iodex Double, while name mentioned on Form 5 is Herb Active Balm, needs clarification in this regards.
M/s USAS Corporation, Flat No. C, 1st Floor Crown Tower Pakki Thatti, Samanabad, District Lahore (Poultry) agent of M/s Mistav Ilac Ve Tavukculuk San Tic Ltd. Sti., ASO2. VE3. Organize Sanayi Bolegesi Alci mah. 2010 Cad. No: 15 Temelli-Sincan/Ankara (E. No. 00785)		
139.	Calci-Phos+	Deferred with final opportunity for the provision of following documents: i. Valid COA of finished product is required. ii. Long term and accelerated stability studies according to the requirement of Zone IV A is required.
140.	Phytomis Respiro	Deferred with final opportunity for the provision of following documents: i. Valid COA of finished product is required. ii. Long term and accelerated stability studies according to the requirement of Zone IV A is required. iii. Notarized and countersigned free sale certificate is not given, in this regards notarized and countersigned Free sale certificate is required.
M/s Meezab International Jahanian located at the address Near Bilal Mosque, Fareed Abad, Jahanian, Punjab-Pakistan agent of M/s Lexington Enterprises PTE Ltd Singapore (E. No. 00765)		
141.	Futuristic C	Deferred with final opportunity for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> i. Lytic Phages are viruses, justification of use of Lytic Phages as health product under SRO 412 is required. ii. Signed and Stamped Form 5 is required. iii. Long term and accelerated stability studies according to requirement of Zone IV A are required. iv. Free sale certificate issued by Singapore Food Agency is not notarized by Law representative in the country of origin, needs clarification in this regards. v. COA of finished product is required.
142.	Futuristic S	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Lytic Phages are viruses, justification of use of Lytic Phages as health product under SRO 412 is required. ii. Signed and Stamped Form 5 is required. iii. Long term and accelerated stability studies according to requirement of Zone IV A are required. iv. Free sale certificate issued by Singapore Food Agency is not notarized by Law representative in the country of origin, needs clarification in this regards. v. COA of finished product is required.
M/s Aims Health Solutions, 194-N Phase-8, DHA, Lahore Cantt agent of M/s Albors SRL, Via Aurelio Saffi, 9 Milano (operatively in Via Arturo Tosanelli, 14-Buccinasco), Italy. (E. No. 00990)		
143.	Albovit Super Fix	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Free sale certificate depict that brand name is Super fix while CoA of finished product shows that brand name is Albovit Super Fix, needs clarification in this regard. ii. Accelerated and long term stability studies data (according to zone IV A requirement) is required. iii. Justification of use of esmectite (bentonite), a toxin binder as health product is required. iv. Testing specification of saccharomyces cerevisiae is required.
144.	Albovit Diurex	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Free sale certificate depict that brand name is Diurex while CoA of finished product shows that brand name is Albovit Diurex, needs clarification in this regard. ii. Accelerated and long term stability studies data (according to zone IV A requirement) is required iii. Ammonium chloride is added in common molecules list.
145.	Albovit ADEK	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Accelerated and long term stability studies data (according to zone IV A requirement) is required.
146.	Albovit Rapid C	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Free sale certificate depict that brand name is Rapid C while CoA of finished product shows that brand name is Albovit Rapid C, needs clarification in this regard. ii. Accelerated and long term stability studies data (according to zone IV A requirement) is required.
M/s Base6 (Pvt) Ltde., E-216, Street No.6, Cavalry Ground, Lahore agent of M/s Blackmores Ltd., 20 Jubilee Avenue, Warriewood, NSW 2102, Australia (E. No. 00442)		
147.	Blackmores Glucosamine	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Glucosamine is included in the list of common molecule. ii. Long term and accelerated stability studies according to the requirement of Zone IV A are required.
M/s CCL Pharmaceuticals (Pvt.) Ltd., 65-Industrial Estate, Kot Lakhpat, Lahore-Pakistan agent of M/s Jiangsu Kanion Pharmaceuticals Co. Ltd., Economic Development Zone, Jiangning Industrial Town, China (E. No. 00470)		
148.	Myo Q+ Softgel Capsule	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Free Sale certificate has been issued by Lianyungang Kangia International Co., Ltd., China, in this regard it is submitted that Free sale certificate is to be attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin.

S.No (1)	Brand name (2)	Decision (3)
		ii. Reference is made w.r.t agency agreement it is revealed that M/s CCL Pharmaceuticals, Lahore is not importing any product in finished form, needs clarification in this regards.
M/s KAM Pharma, located at the address, Office 125 Street No. 1, Din Colony, Sargodha agent of M/s Emivest Feedmill, Vietnam Company Limited, Lot A-11A-CN, Bau Bang Industrial Zone, Lai UyenTown, Bau Bang District, Binh Duong Province, Vietnam (E. No. 01011)		
149.	Energetic Vita C 10%	Deferred with final opportunity for following reasons: i. Original Free Sale certificate is required.
150.	Electrolytes Stamina	Deferred with final opportunity for following reasons: i. Product resembles to ORS composition, added in the list of common molecule. ii. Signed and Stamped form 5 is required. Original Free Sale certificate is required.
M/s Poulvet Tradings, Flat # T-5, Shabnam Centre, Shalimar Link Road, Mughalpur, Lahore-Pakistan agent of M/s Vimar Gida Tarim VE Hayvancilik San. Tic. A.S., Istanbul Anadolu Yakasi Org. San. Bolgesi Aydinli Mah.2, San. Cad. No.16 Tuzla Istanbul, Turkey (Veterinary) (E. No. 00616)		
151.	Vimprozyme Liquid Premix	Deferred as formulation contains Xylanase, Amylase which are included in the list of common molecule.
M/s Matrix Pharma Pvt, Ltd Plot No. 12, Sector-15, Korangi Industrial Area, Karachi-74900 agent of M/s Anabio Research and Development JSC Vietnam (E. No. 0015)		
152.	Spobio Onco	Deferred with final opportunity for following reasons: 1. Testing specification (numeration) and Characterization o each probiotic is required. 2. Specific stain of each probiotic is required. 3. Brand name mentioned on real time stability studies data, COA of finished and Certificate of Free Sale product is Spobio Chemo while given on form 5 is Spobio Onco, needs clarification in this regards. 4. Submitted free sale certificate is issued by Import Export Administration Department of the Ministry of Industry and Trade of Socilist Republic of Vitnam, while free sale certificate is to be attested by concern regulatory body in the country of origin.
153.	Spobio SOS	Deferred with final opportunity for following reasons: 1. Testing specification (numeration) and Characterization o each probiotic is required. 2. Specific stain of each probiotic is required. 3. Submitted free sale certificate is issued by Import Export Administration Department of the Ministry of Industry and Trade of Socilist Republic of Vitnam, while free sale certificate is to be attested by concern regulatory body in the country of origin.
154.	Spobio Soft	Deferred with final opportunity for following reasons: 1. Testing specification (numeration) and Characterization o each probiotic is required. 2. Specific stain of each probiotic is required. 3. Brand name mentioned on real time stability studies data, COA of finished and Certificate of Free Sale product is Spobio Bon while given on form 5 is Spobio Soft, needs clarification in this regards. 4. Submitted free sale certificate is issued by Import Export Administration Department of the Ministry of Industry and Trade of Socilist Republic of Vitnam, while free sale certificate is to be attested by concern regulatory body in the country of origin.
M/s Sana Traders International, located at the addressHouse No. 797-C, Bata Chowk, Gulgasht Colony Multan agent of M/s Dilus Laboratories S.L, Poligonon Industrial EL Bullo, C. Mestral, 7- 08507 Santa Eugenia de Berga, Barcelona, Spain (E. No. 00957)		
155.	Vitamin AD3ECK	Deferred with final opportunity for following reasons: 1. Signed and stamped form 5 is required. 2. Accelerated stability studies data is required. 3. Brandname mentioned on CoA of finshed product is Corion Vitamin AD3CK while given on form 3 is Vitamin AD3CK, ,needs clarification in this regard. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required.

S.No (1)	Brand name (2)	Decision (3)
156.	Coriotox	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion Coriotox while given on Form 3 is coriotox, needs clarification in this regard. 3. Accelerated and long term stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required. 5. Justification of use of Bentonite along with whole formulation, toxin binder as health product is required.
157.	Electrolytes S	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion Electrolyte S while given on Form 3 is Electrolyte S, needs clarification in this regard. 3. Accelerated and long ther stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required. 5. Product resembles with ORS, added in common molecules list.
158.	Hidra Plus	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion hydra plus while given on Form 3 is hidra plus, needs clarification in this regard. 3. Accelerated and long term stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required. 5. Glucose is added in common molecules list.
159.	Chick Pro	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion chick pro while given on Form 3 is chick pro, needs clarification in this regard. 3. Accelerated and long term stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required. 5. CoA of finished product indicating chemical assay of each active ingredient is required.
160.	Prevencor	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion Prevencor while given on Form 3 is Prevencor, needs clarification in this regard. 3. Accelerated and long term stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required. 5. Dextrose is added in common molecules list.
161.	Vitesel Plus	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion vitesel plus while given on Form 3 is vitesel plus, needs clarification in this regard.

S.No (1)	Brand name (2)	Decision (3)
		3. Accelerated stability studies data is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required.
162.	Vitesel	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion vitesel while given on Form 3 is vitesel, needs clarification in this regard. 3. Accelerated stability studies data is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required.
163.	Liver Tonic	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion liver tonic while given on Form 3 is liver tonic, needs clarification in this regard. 3. Accelerated and long ther stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required.
164.	Renacor	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion renacor while given on Form 3 is renacor, needs clarification in this regard. 3. Accelerated and long ther stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required. 5. Mannitol is added in common molecules list. 6. CoA of finshed product w.r.t chemical assay of each ingredient is required.
165.	Aminovita Forte	Deferred with final opportunity for following reasons: 1. Signed and stamped Form 5 is required. 2. Brand name given on CoA of finished product is Corion aminovita forte while given on Form 3 is Aminovita forte, needs clarification in this regard. 3. Accelerated and long ther stability studies data w.r.t chemical assay of each active ingredient is required. 4. Free sale certificate to be issued by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required.
M/s Sattar Agro & Livestock, Rana Nasir Road, Off Defense Road, Bohhtian Chowk, Lahore agent of M/s Zhejiang Vega Bio-Technology Co., No. 3 Building Xiaoshu Industrial Estate, Melxi Town, Huzhou, China (E. No. 01150)		
166.	VegaButyryn 600	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Actual strength of each active ingredient is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data to be issued by principal manufacturer is required. iv. required. v. CoA of raw material and finished product is required. vi. Testing specification of tributyrin is required.
167.	Vegacid Plus	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Actual strength of each active ingredient is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data to be issued by principal manufacturer is required.

S.No (1)	Brand name (2)	Decision (3)
168.	Active Three	Deferred with final opportunity for following reasons: i. Free sale certificate is required. ii. Signed and stamped Form 5 is required. iii. Actual strength of each active ingredient is required. iv. Accelerated and long term stability studies (according to zone IVA requirements) data to be issued by principal manufacturer is required. v. Specific strain of each probiotic is required. vi. Testing specification (enumeration) and characterization of each probiotic is required. vii. CoA of raw materials and of finished product is required.
169.	Velyga-L	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Actual strength of each active ingredient is required rather than strength given in range. iii. Accelerated and long term stability studies (according to zone IVA requirements) data to be issued by principal manufacturer is required.
170.	Laurin-Cu	Deferred with final opportunity for following reasons: i. Free sale certificate is required. ii. Signed and stamped Form 5 is required. iii. Actual strength of each active ingredient is required. iv. Accelerated and long term stability studies (according to zone IVA requirements) data to be issued by principal manufacturer is required.
<p align="center">M/s Schiwo Pakistan located at the address 11-G, Shah Rukan-e-Alam Colony, Multan –Pakistan agent of M/s Zhengzhou Bairui Animal Pharmaceutical Co., Ltd., Xinzheng City Baqiangxian on the North Side of The Xin Chun Road No.2, China (E. No. 00687)</p>		
171.	Bory-Feedex	Deferred with final opportunity for following reasons: i. Long term stability studies data according to zone IVA is required. ii. Evidence is required that Henan Province Animal Husbandry Bureau is authorized by Government of China for issuance of free sale certificate. iii. Safety profile of Vitamin K3 in veterinary use is required. iv. Product contains probiotics (bacillus subtilis and bacillus licheniformis) as in-active ingredients, needs clarification in this regard since probiotic play important role in any formulation. v. Testing specification (enumeration) and characterization of each probiotic is required.
172.	Bory-Vitazyme	Deferred with final opportunity for following reasons: i. Long term stability studies data according to zone IVA is required. ii. Evidence is required that Henan Province Animal Husbandry Bureau is authorized by Government of China for issuance of free sale certificate.
173.	Bory-Respirator :	Deferred with final opportunity for following reasons: i. Long term stability studies data according to zone IVA is required. ii. Evidence is required that Henan Province Animal Husbandry Bureau is authorized by Government of China for issuance of free sale certificate.
174.	Bory-Hygain	Deferred with final opportunity for following reasons: i. Long term stability studies data according to zone IVA is required. ii. Evidence is required that Henan Province Animal Husbandry Bureau is authorized by Government of China for issuance of free sale certificate.
<p align="center">M/s Schiwo Pakistan 11-G, Shah Rukan-e-Alam Colony, Multan agent of M/s. Shafaq Industrial Company for Veterinary Drugs & Feed Additives, King Abdullah II Bin Al Hussain Industriail City Sahab, Amman-e-Shemeisani-Madina Trading Center (E. No. 00805)</p>		
175.	Shafa-Vexin	Deferred with final opportunity for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		i. Accelerated stability studies data is required.
M/s Zuram Brothers, located at the address 522-Hamza Block, Street No. 6, Green View Colony, Faisalabad agent of M/s Artan, 35 rue Paul Boumer, 22 950 Tregueux- France (Principle Manufacturer M/s Artimon, 5 rue Brindejonc des Moulinais – 22190, Plerin, France) (E. No. 00958)		
176.	Hepasol Forte (Oral Solution) Liquid	Deferred with final opportunity for following reasons: i. Long term stability studies data according to requirement of Zone IV A is required.
M/s MK Pharmaceutical Group., 307-B, Gulshan-e-iqbal Colony, Near Aziz Fatima College for Women, Risalaywala Road, Faisalabad agent M/s Lek Veterina D.o.o, Lipovci 251A, 9231 Beltinci, Slovenia (E. No. 01031)		
177.	Multiaminosele	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Accelerated and long term stability studies (according to zone IVA requirements) data is required. iii. original Free sale certificate is required.
178.	Dr Calcium	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Accelerated and long term stability studies (according to zone IVA requirements) data is required. iii. original Free sale certificate is required.
179.	Hepavit Plus	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Accelerated and long term stability studies (according to zone IVA requirements) data is required. iii. Free sale certificate to be attested by concerned regulatory body in country of origin, countersigned by embassy of Pakistan is required
180.	BronhiMint Plus	Deferred with final opportunity for following reasons: i. Signed and stamped Form 5 is required. ii. Accelerated and long term stability studies (according to zone IVA requirements) data is required. iii. Original Free sale certificate is required.
M/s Golden Harvest located at the address 49C, 24th Commercial Street, Phase 2 Extension DHA, Karachi-Pakistan agent of M/s Kaesler Nutrition GmbH, ZepelinstraBe 3, 27472 Cuxhaven, Germany (E. No. 00744)		
181.	Lovit Granule BX	Deferred with final opportunity for following reasons: i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required. iv. Distribution rights documents issued by M/s Kaesler Nutrition, Germany depicts that M/s Golden Harvest, Karachi will be exclusive distributor for their range of liquid feed supplements (lovit) in Pakistan while applied product's dosage form is powder not liquid form, needs clarification in this regard.
182.	Lovit EC + SE Liquid	Deferred with final opportunity for following reasons: i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required.
183.	Lovit Hepavent Liquid	Deferred with final opportunity for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required.
184.	Lovit LC-Energy Liquid	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required.
185.	Lovit Probiotic	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required. iv. Testing specification (enumeration) and characterization of probiotic is required.
186.	Lovit Breeze Liquid	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required.
187.	Lovit Phos Plus Liquid	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required.
188.	Lovit Cool Liquid	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> i. Evidence is required either Lower Saxony State office for consumer Protection and Food safety authorized by government of Germany for issuance of free sale certificate. ii. Free sale certificate was issued on 25-11-2019 and have validity of six months while firm submitted application for grant of product enlistment on 06-10-2020, in this regard valid free sale certificate is required. iii. Accelerated and long term stability studies (according to zone IVA requirements) data is required.

S.No (1)	Brand name (2)	Decision (3)
M/s MedOn Group, located at 3rd Floor, Khyber Plaza, Nai Abadi, Alipur, Islamabad agent of M/s Thompson & Capper Limited, located at 1-13 Hardwick Road, Astmoor Industrial Estate, Runcorn, WA7 1PH, United Kingdom (E. No. 01120)		
189.	Fertility Plus Capsule	Deferred with final opportunity for following reasons: i. Brand name to be changed and alternate name (s) to be submitted by principal manufacturer on company letter head.
M/s. Base 6 (Pvt) Ltd, E-216, Street No.6, Cavalry Ground, Lahore agent of M/s. Factor Group of Nutritional Companies Inc., 1550 United Boulevard, Coquitlam, British Columbia, Canada (E. No. 00316)		
190.	Webber Naturals Collagen30 Hydrate	Deferred with final opportunity for following reasons: i. Hyaluronic Acid is included in the list of common molecule. ii. Long term and accelerated stability studies according to the requirements of Zone IV A are required. iii. Formulation on Form 5 and International trade certificate issued by Consumer Health Canada (Authorized by Health Canada) is not identical w.r.t to Ceramosides™ Phytoceramide Ext (Triticum aestivum) Standardized to 3.5% Glucosylceramides and 405 Digalactosyl Diglyceride, needs clarification in this regards. iv. This document also shows that M/s WN Pharmaceutical Ltd., BC, Canada is applicant/exporter of said product and manufacturer if M/s Factor Group of Nutritional Companies Inc., BC, Canada, while such information is not depicted in form 6, needs clarification in this regards. v. Clarification is required with respect to 2 different principal manufacturers i.e. M/s Natural Factors Nutritional Products Ltd. (E. No. 0095) and M/s. Factor Group of Nutritional Companies Inc. (E. No. 00316) having same manufacturing site addresses
M/s A.S.M. Pharma, 47-Basement, Al-Miraj Arcade, Chouburji, Lahore agent of M/s Methodo Chemical s.r.l., via del lavoro 9, 46020 Marcaria, Italy (E. No. 00644)		
191.	M.Poultry Mineral Premix (Growthpromoter)	Deferred with final opportunity with following reasons: i. Original and valid Free sale certificate is required. ii. Long term and accelerated stability studies data according to the requirement of Zone IV A are required. iii. COA of finished product is required.
192.	M. Poultry Vitamin Premix (Growth Promoter)	Deferred with final opportunity for following reasons: i. Original and valid Free sale certificate is required. ii. Long term and accelerated stability studies data according to the requirement of Zone IV A are required. iii. COA of finished product is required.
193.	Methodo Vitamin C	Deferred with final opportunity for following reasons: i. Original and valid Free sale certificate is required. ii. Long term and accelerated stability studies data according to the requirement of Zone IV A are required. iii. COA of finished product is required.
M/s IBL Healthcare Limited, 9th Floor, NIC Building, Abbasi Shaheed Road, Karachi agent of M/s Nestle Health Sciences GmbH, Werk Osthofen Dr.-Wander-StraBe 11, 67574 Osthofen, Germany (E. No. 00896)		
194.	Impact Oral Tropical	Deferred with final opportunity for following reasons: i. Long term and accelerated stability studies according to the requirement of Zone IV A. ii. Brand name mentioned on Form 5 is Impact Oral Tropical and name mentioned on Free sale certificate and COA is Impact Oral Tropical 6, needs clarification in this regards.
195.	BOOST Beneprotein	Deferred with final opportunity for following reasons: i. Long term and accelerated stability studies according to the requirement of Zone IV A.
M/s Acti Health Food, Suite No. 1 shireen Arcade Plot No. A-41, K.U.C.H.S. Block 7 & 8, Karachi agent of M/s Thompson & Capper, 9-13 Hardwick Road, Astmoor Industrial Estate, runcorn, Cheshire, WA7 1PH(E. No. 0045)		
196.	Hairfolic Man Tablets	Deferred with final opportunity for following reasons: i. Certificate of Free sale issued by Environment, Food and Rural Affairs, Rural Payments Agency UK depicts that Vitabiotics Ltd., London UK is manufacturer/Owner of said

S.No (1)	Brand name (2)	Decision (3)
		<p>product, while such no information is available on form 6, needs clarification in this regards.</p> <p>ii. Evidence is required either Rural Payments Agency is authorized by Government of UK for issuance of Free sale certificate.</p> <p>iii. N-Acetyl Cysteine is included in the list of common molecule.</p> <p>iv. Long term stability studies according to requirement of Zone IV A is required.</p> <p>v. COA of Finished product is required.</p>
M/s Schazoo SPL Consumer Healthcare, located at the address 71-B, C/2, Gulberg III, Lahore agent of M/s Unipharma LLC, 10200 NW 67th St., Tamarac, FL 33321-6404, USA (E. No. 01173)		
197.	GlutaDose Wellness Oral Solution	<p>Deferred with final opportunity for following reasons:</p> <p>i. Signed and stamped form 5 is required.</p> <p>ii. Testing specification/ method of Proprietary Blend Gluta Dose Wellness</p> <p>iii. L-Glutathione Acerola Extract is required.</p> <p>iv. Long term and accelerated stability studies indicating chemical and microbiological assay of each active ingredient, as per the requirement of Zone IV A.</p> <p>v. Incomplete long term stability studies data of 12 months is submitted by the firm, while shelf life of 2 years is being given as condition of Form 7, needs clarification in this regards.</p> <p>vi. The submitted free sale certificate is issued by the Official Economic Development and International Trade Office for the state of Florida while free sale certificate is required to be attested the concern regulatory body in the country of origin, and countersigned by the Embassy of Pakistan in the country of origin.</p>
M/s. Nova Medicines (Pvt.) Ltd., 406, Panorama Centre No. 2, Raja Ghazanfar Ali Khan Road, Saddar, Karachi-Pakistan agent of M/s. Korea United Pharm. Inc., 22, Nonhyeon-ro 121-gill, Gangnam-gu, Seoul, KOREA (E. No. 00219)		
198.	Homtamin Ginseng Ext. Soft Capsule	<p>Deferred with final opportunity for following reasons:</p> <p>i. Provision of Notorized and attested copy of Free sale certificate counter signed by the Embassy of Pakistan in the country of origin.</p>
M/s Gee Vet International, office. 11/12, first floor, Naz Medicine Market Namak Mandi, Peshawar-Pakistan agent of M/s Inner Mongolia Huatain Pharmaceutical Co. Ltd., Economic Development Zone, Yuanbaoshan District ChiFeng city, Inner Mongolia, P.R. China (Veterinary) (E. No. 00602)		
199.	Control-Viral Double Strength	<p>Deferred with final opportunity with following reasons:</p> <p>i. Application not submitted on prescribed form 5.</p> <p>ii. Brand name is not appropriate.</p> <p>iii. Stability Studies data according to the requirement of Zone IV-A not provided.</p> <p>iv. Free sale certificate notorized and countersigned by the embassy of Pakistan in the country of is required.</p> <p>v. GMP Certificate not provided.</p> <p>vi. Pack Size not given.</p>
M/s Al-Muzammal Traders, located at the address Office No. 6-7, 2nd Floor, Sharjah Centre, Shadman Market, Lahore agent of M/s Hebei Junyu Pharmaceutical Co., Ltd., Douyu Industrial Zone, Luancheng District, Shijiazhuang City Hebei Province, China (E. No. 01062)		
200.	Liver Protector	<p>Deferred with final opportunity for following reasons:</p> <p>i. Form 5 is not stamped and signed by the applicant and is printed on company letter head.</p> <p>ii. Free Sale certificate is required.</p> <p>iii. Undertaking on stamp paper regarding correctness of application content.</p>
201.	Vita-Electro Best	<p>Deferred with final opportunity for following reasons:</p> <p>i. Form 5 is not stamped and signed by the applicant and is printed on company letter head.</p> <p>ii. Free Sale certificate is required.</p>

S.No (1)	Brand name (2)	Decision (3)
		iii. Undertaking on stamp paper regarding correctness of application content.
202.	VE + SE 200mg	Deferred with final opportunity for following reasons: i. Form 5 is not stamped and signed by the applicant and is printed on company letter head. ii. Free Sale certificate is required. iii. Undertaking on stamp paper regarding correctness of application content
203.	Alpha Stem	Deferred with final opportunity for following reasons: i. Form 5 is not stamped and signed by the applicant and is printed on company letter head. ii. Free Sale certificate is required. iii. Undertaking on stamp paper regarding correctness of application content
204.	KL Protect	Deferred with final opportunity for following reasons: i. Form 5 is not stamped and signed by the applicant and is printed on company letter head. ii. Free Sale certificate is required. iii. Undertaking on stamp paper regarding correctness of application content.
205.	Vitamin C 25% Solution	Deferred with final opportunity for following reasons: i. Form 5 is not stamped and signed by the applicant and is printed on company letter head. ii. Free Sale certificate is required. iii. Undertaking on stamp paper regarding correctness of application content.
206.	VE + SE 100mg	Deferred with final opportunity for following reasons: i. Form 5 is not stamped and signed by the applicant and is printed on company letter head. ii. Free Sale certificate is required. iii. Undertaking on stamp paper regarding correctness of application content.
207.	Aminovit Best	Deferred with final opportunity for following reasons: i. Form 5 is not stamped and signed by the applicant and is printed on company letter head. ii. Free Sale certificate is required. iii. Undertaking on stamp paper regarding correctness of application content.
M/s Nutri Tech, Located at the address 55-C, Malik Naeem Street, Aitchison Society, Raiwind Road, Lahore agent of M/s Kemira Europa N.V. Toekomstlaan 42, 2200 Herentals, Belgium (E. No. 00851)		
208.	Kemzyme Plus Concentrate Dry	Deferred with final opportunity for following reasons: i. Stability Studies data according to the requirement of Zone IV-A not provided.
209.	Kemzyme Plus Dry	Deferred with final opportunity for following reasons: i. Stability Studies data according to the requirement of Zone IV-A not provided.
M/s Brand Station, 89 A2, Wapda Town Extension, Lahore agent of M/s Sen Tarim Ve Sanayi A.S, Bugdayli Mah. Tastepe Mevkii, Bandirma Organize, Sanayi Bolgesi, 4. Cadde No.5, Gonen/Balikesir, Turkey (E. No. 01147)		
210.	Nutri Minoil	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required.

S.No (1)	Brand name (2)	Decision (3)
		ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
211.	Nutri C+ WS Powder	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
212.	Nutri E-Sell	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
213.	Nutri ADEK-C Liquid	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
214.	Nutri AC Acid Liquid	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required.

S.No (1)	Brand name (2)	Decision (3)
		ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
215.	Nutri Livertonic	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
216.	Nutri Selen-E	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
217.	NutriToxin Binder	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
218.	Nutri Biyo	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required.

S.No (1)	Brand name (2)	Decision (3)
		ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
219.	Nutri Z-Powder+	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
220.	Nutri Broiler Finisher Concentrate Premix 2.5%	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
221.	Nutri Broiler Starter Concentrate Premix 2.5%	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required. ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
222.	Nutri Broiler Grower Concentrate Premix 2.5%	Deferred with final opportunity for following reasons: i. Application on Form 5 as prescribed under SRO 412 (I) 2014 not provided. ii. Testing specification of raw material and finished product not provided. iii. Validation data of product is not product. iv. COA of active ingredients and Finished product is not provided. v. Shelf life and storage conditions not provided. vi. Long term and accelerated stability studies according to requirement of Zone IV A is not provided. vii. Evidence of clinical safety and efficacy is required. iii. Packaging and labeling details are required.

S.No (1)	Brand name (2)	Decision (3)
		ix. Notorized and attested copy of free sale certificate counter signed by the Embassy of Pakistan in Country of Origin is required.
M/s Aman Traders, 11/1 D, People Colony No. 1, Faisalabad agent of M/s PEKANA Naturheilmittel GmbH Raiffeisenstrasse 15, 88353 Kisslegg, Germany (E. No. 0030)		
223.	Arnica Montana C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
224.	Arsenicum Album C 30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required
225.	Kalium Phosphoricum C200 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
226.	Selenium C200 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
227.	Gelsemium C200	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
228.	China C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
229.	Thuja C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
230.	Calcium Carbonicum HAHN C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
231.	Lycopodium C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
232.	Selenium C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
233.	Carbo Vegetabilis C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
234.	Absenicum Album C200 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided.

S.No (1)	Brand name (2)	Decision (3)
		ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
235.	Calcium Fluoratum C200 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
236.	Hepar Sulfuris C30 Potency	Deferred with final opportunity with following reasons: i. Signed and stamped Form 5 not provided. ii. Stability studies data according to the requirement of Zone IV A. iii. Free sale certificate/CoPP is required. iv. COA of finished product is required.
M/s Inter Care Animal Health, Flat # 12, 2nd Floor, United Center, Shamsabad, Murree Road, Rawalpindi agent of M/s Viet Anh Joint Venture Investment Joint Stock Company, Lien Phuong Industry Zone, Lien Phuong Commune, Thuong Tin District, Ha Noi City, Vietnam (E. No. 01086)		
237.	Az.Biozyme One Powder	Deferred as Formulation contains Silymarin, which is included in the list of common molecule.
238.	VIA.HEPA LIQUID	Deferred as Formulation contains Sodium bicarbonate, which is included in the list of common molecule.
239.	ULYTE VIT-C ORAL SOLUBLE POWDER	Deferred as Formulation contains Sodium bicarbonate, which is included in the list of common molecule.
M/s Abbott Laboratories (Pakistan) Ltd, Opp. Radio Pakistan Transmission Centre, Hyderabad Road, Landhi Karachi-75120 agent of M/s Abbott Manufacturing Singapore Pvt Ltd, 26 Tuas South Avenue 10, Singapore (E. No. 0009)		
240.	Pediasure Kid 3 Plus (Vanilla Flavor)	Deferred with final opportunity for following reasons: i. Stability studies data Pediasure Kid 3 Plus along with 850g as pack size (applied by the firm) is required. However, firm submitted stability studies data of Pediasure Triplesure MR Powder Vanilla, which is not required. ii. Copy of Free sale certificate issued by Singapore Food Agency does not depict any statement which clearly shows that said product is freely available in the country of origin, needs clarification in this regards.
M/s Health Supplement incorporated S 38A, 2nd floor Shahnaz Arcade Shaheed-e-Millat Road Karachi agent of M/s Captek Softgel international, 16218 Arthur street Cerritos, CA 90703, USA (E. No. 00469)		
241.	Marathon Plus Tablet	Deferred till finalization of common molecule list.
M/s Pak Care International Company, Al-Qadir Garden 203 RB Mana wala, Faisalabad – Pakistan agent of M/s Reva Tarim Kimya San. Vet Tic. Ltd. STI, Tatlicak MAH Vatan Sanayi Sitesi Kavaf Sokak No: 43-45-47-49-51 Karatay, Konya – Turkey (Veterinary) (E. No. 00527)		
242.	Retox Toximix	Deferred with final opportunity for the provision of following documents: • Stability Studies Data not provided. • GMP Certificate not provided. • Free Sale Certificate is not legalized and counter signed by the Embassy of Pakistan. Moreover, some pages of Free Sale certificate are printed on company letter head. • Clarification is required regarding role of Toxin Binding w.r.t Alternative Medicines and Health Products (Enlistment) Rules, 2014.
243.	Mentostar	Deferred with final opportunity for the provision of following documents: • Stability Studies Data not provided. • GMP Certificate not provided. • Free Sale Certificate is not legalized and counter signed by the Embassy of Pakistan. Moreover, some pages of Free Sale certificate are printed on company letter head.
244.	Super ADECK	Deferred with final opportunity for the provision of following documents: • Stability Studies Data not provided. • GMP Certificate not provided.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Free Sale Certificate is not legalized and counter signed by the Embassy of Pakistan. Moreover, some pages of Free Sale certificate are printed on company letter head.
245.	Reva ADEKC	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies Data not provided. GMP Certificate not provided. Free Sale Certificate is not legalized and counter signed by the Embassy of Pakistan. Moreover, some pages of Free Sale certificate are printed on company letter head.
246.	Reva Mycotox Plus	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies Data not provided. GMP Certificate not provided. Free Sale Certificate is not legalized and counter signed by the Embassy of Pakistan. Moreover, some pages of Free Sale certificate are printed on company letter head. Clarification is required regarding role of Toxin Binding w.r.t Alternative Medicines and Health Products (Enlistment) Rules, 2014.
247.	Liver Active	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies Data not provided. GMP Certificate not provided. Free Sale Certificate is not legalized and counter signed by the Embassy of Pakistan. Moreover, some pages of Free Sale certificate are printed on company letter head.
<p align="center">M/s Fasco Biocare Supplies, located at the address 140-Allama Iqbal Shopping Center, Jahanina District Khanewal-Pakistan agent of M/s Ben Invest Srl, Via Luigi Einaudi n°12 LocBettolino 25030 Brandico BS Italia [Principal Manufacturer: M/s Eurofeed Technologies spa, Via Luigi Einaudi n°12 Loc. Bettolino BS Italia] (E. No. 00656)</p>		
248.	Immunofas Plus	Deferred as formulation contains Glucosamine which is included in common molecules list
249.	Electrofas	Deferred as Formulation contains Sodium bicarbonate, which is included in the list of common molecule.
<p align="center">M/s High Profile Poultry Services Located at the address P-8 Near National Bank of Pakistan Jail Road Faisalabad agent of M/s ALPHAFACETS HEALTH SOLUTIONS BVBA Diamanstraat 8/101 2200 herentals, Belgium (E. No.00844)</p>		
250.	Alphaliv Liquid	Deferred since the formulation contains Glucosamine, which is included in the list of common molecule.
<p align="center">M/s Abbasi Associate., 997-B, Jamil Chowk, Main Road Samanabad, Faisalabad agent of M/s PlusVet Qingdao Animal Health Co., Ltd. Zhengwang Road 2, Environment Protect Industry Park, 266201 Jimo City, Qingdao, China (E. No. 00855)</p>		
251.	PlusProtect Digestive+ Powder	Deferred with final opportunity for the change of brand name.
<p align="center">M/s International Chempharma (Pakistan), located at the address House No. 397- Block B1 Johar Town, Lahore agent of M/s Nufoer S.L, C/Chile, 10 of 32, 28290 Las Matas, Las Rozas, Madrid, Spain (E. No. 00954)</p>		
252.	Nufotox	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Form -5 is missing. Stability Studies Data provided not as per prescribed conditions of Zone IV-A. Original GMP not provided. Free Sale Certificate not provided. Clarification is required regarding role of Hydrated Sodium Calcium Aluminum Silicates (Sepiolite) w.r.t SRO 412(I)/2014.
253.	Nufoliver Guard	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Form -5 is missing. Stability Studies Data provided not as per prescribed conditions of Zone IV-A. Original GMP not provided. Free Sale Certificate not provided.

S.No (1)	Brand name (2)	Decision (3)
254.	Nufo-Aminovit	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form -5 is missing. • Stability Studies Data provided not as per prescribed conditions of Zone IV-A. • Original GMP not provided. • Free Sale Certificate not provided.
255.	Nufo-Selenvit	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form -5 is missing. • Stability Studies Data provided not as per prescribed conditions of Zone IV-A. • Original GMP not provided. • Free Sale Certificate not provided.
256.	Nufo ADECK	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form -5 is missing. • Stability Studies Data provided not as per prescribed conditions of Zone IV-A. • Original GMP not provided. • Free Sale Certificate not provided.
M/s Ichhra Vety Medicine, located at 177 Shami Park, Chungi Amar Sidhu, Ferozpur Road, Lahore agent of M/s Vietvet Pharmaceutical Joint Stock Company, Block B103 – B104, Street 4, Thai Hoa Industrial Park, District DuchHoa District, Long An Province, Vietnam (E. No.00995)		
257.	Livergain Liquid	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> • Glucosamine is added in common molecules list. Moreover, strength of cynara artichoke is required. • Brand name is not appropriate, needs to be changed.
258.	Noramune CE	Deferred since Formulation contains Sodium bicarbonate, which is included in the list of common molecule.
259.	Booster Liquid	Deferred for change of brand name
260.	Nortox Gold	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> • Change of brand name. • Description of specific species of yeast is required. • Justification of use of Clinoptillites, Montomorillonites and Aluminum silicate.
261.	Imunesystem	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> • Justification for use of hydrolyzed Nucleotides and Peptides in formulation.
262.	Hepasure Liquid	Deferred as formulation contains Glucosamine which is added in common molecules list.
263.	Promune	Deferred with final opportunity for following reasons: Justification for use of hydrolyzed Nucleotides and Peptides in formulation.
M/s Glikes Pharma (Pvt) Ltd., located at the address, Office No. 9, Unit 2, Nazar Plaza Satellite Town, Rawalpindi agent of M/s Shandong Yuwang Pharmaceutical Co. Ltd., No. 2731 Tongqu Road, Yucheng City, Dezhou City, Shandong, China (E. No.01026)		
264.	Sternum Multi Tablet	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> • Original notarized free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of origin.
265.	Vigral Plus Tablet	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> • Original notarized free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of origin.
266.	Diaon-D Tablet	Deferred with final opportunity for following reasons: <ul style="list-style-type: none"> • Original notarized free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of origin.
M/s Marush (Pvt.) Ltd., 123-K, Model Town, Lahore agent of M/s Agraplan Farmaca B.V. Maalstoel 6, 7773NN Hardenberg, The Netherlands (Principal Manufacturer: M/s Feramed B.V, Veemweg 1, 3771MT Barneveld, The Netherlands) (E. No. 01104)		

S.No (1)	Brand name (2)	Decision (3)
267.	Bioplan Groei	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A
268.	Vitaplan C Oral	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A
269.	Aminovitaplan	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A
270.	Omnivitamin Super W.O.	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A Strength of potassium chloride as an active ingredient is required.
271.	Hepavet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A
272.	Vitaplan ESE	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A. Halal origin certificates are required for crude protein, crude fat. Monomers of crude proteins and crude fats are required from which these are prepared. Strength of crude protein and crude fiber show zero percent, clarification is required in this regard.
273.	Magnoplan	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A. Strength of magnesium chloride and potassium chloride as active ingredients are required.
274.	Vitaplan DCP	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Stability Studies data not provided as per prescribed conditions of Zone IV-A. Strength of calcium chloride as an active ingredient is required.
M/s. Base6 (Pvt) Ltd, E-216, Street No.6, Cavalry Ground, Lahore agent of M/s WN Pharmaceuticals Ltd., 2000 Brigantine Drive, Coquitlam BC Canada V3K 7B5 (Principal Manufacturer M/s. Factor Group of Nutritional Companies Inc., 1550 United Boulevard, Coquitlam, British Columbia, Canada) (E. No. 00316)		
275.	Most Complete Women's Multi Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Justification regarding the use of additional ingredients, whether they are active or inactive is required. Justification and clarification is required regarding the fruit blend in formulation is required.
276.	Most Complete Men's Multi Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Justification regarding the use of additional ingredients, whether they are active or inactive is required. Justification and clarification is required regarding the fruit blend in formulation is required.
277.	Omega3 with CoQ10 Softgels	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Composition mentioned on form 5 and given on International Trade certificate issued by Consumer Health Products, Canada are not identical, needs clarification in this regards.

S.No	Brand name	Decision
(1)	(2)	(3)
M/s Base6 Pvt, Ltd., E-216, Street No. 6 , Cavalry Grounds, Lahore agent of M/s Natural Factors Nutritional Products Ltd. 1550, United Boulevard, Coquitlam, British Columbia, Canada, V3K 6Y2 (Principal Manufacturer M/s Factors Group of Nutritional Companies Inc., 1550, United Boulevard, Coquitlam, British Columbia, Canada, V3K 6Y2 (E. No. 0095)		
278.	Natural Factors – Liver Health Formula Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none">• Stability studies data of 3 batches not provided as per the prescribed conditions of Zone-IV A.
279.	Natural Factors – Biocgel Softgels	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none">• Stability studies data of 3 batches not provided as per the prescribed conditions of Zone-IV A.
280.	Natural Factors - Hi Potency B Complex Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none">• Stability studies data of 3 batches not provided as per the prescribed conditions of Zone-IV A.
M/s Apex Pharmaceuticals (Pvt) Limited, D-21, A/1, S.I.T.E. Super Highway, Karachi agent of M/s PromoPharma S.p.A, Via Biagio di Santolino, 156 47892 Acquavia Repubblica di San Marino [Manufacturing Site address: Via del Laghetto 110 45021 Badia Polesine (RO), Italy] (E. No. 00526)		
281.	Kalcio Plus Softgel	Deferred with final opportunity for provision following documents: <ul style="list-style-type: none">• Free sale certificate/marketing authorization does not provide information regarding availability of product on free sale in country of origin.



(Ayyaz Ahmad)

Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY.**

MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYY Y
2.								

MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	XYZ Tablet Each tablet contains: Abc (USP)....50mg	XXX	XXX	10's 20's
2.					